Alkermes has been granted a patent for compounds and salts useful in treating conditions related to HDAC inhibition. The method involves administering these compounds to treat cognitive function disorders, impairments, or psychiatric disorders in patients. GlobalData’s report on Alkermes gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Alkermes, was a key innovation area identified from patents. Alkermes's grant share as of February 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11912702B2) discloses a method for treating cognitive function disorders, cognitive function impairments, or psychiatric disorders in individuals in need of such treatment. The method involves administering a therapeutically effective amount of a compound selected from a specific group of compounds. The patent claims outline the process of administering the compound to address the mentioned disorders in subjects requiring treatment.
The patent further details various specific compounds that can be utilized in the method for treating cognitive function disorders, cognitive function impairments, or psychiatric disorders. The claims specify different scenarios and conditions under which the compounds can be administered to achieve the desired therapeutic effect. This patent provides a structured approach to addressing cognitive and psychiatric issues in individuals, offering a potential solution for those in need of such treatment.
To know more about GlobalData’s detailed insights on Alkermes, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.